Page contentsKey factsDecisionKey facts Active Substance RamiprilIndapamide Therapeutic area Cardiovascular diseases Decision number P/0125/2017 PIP number EMEA-002081-PIP01-16 Pharmaceutical form(s) Modified-release tablet Condition(s) / indication(s) Treatment of hypertension Route(s) of administration Oral use Contact for public enquiries Pharmaceutical Works Polpharma SAPolandTel.: +48 58 563 89 44E-mail: iwona.nowak@polpharma.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 05/05/2017DecisionP/0125/2017: EMA decision of 5 May 2017 on the granting of a product-specific waiver for ramipril / indapamide (EMEA-002081-PIP01-16)AdoptedReference Number: EMA/253504/2017 English (EN) (81.41 KB - PDF)First published: 03/07/2017Last updated: 03/07/2017ViewShare this page